Forty eight eyes of 42 patients with choroidal neovascular membranes and age-related macular degeneration who received three different dose regimens of systemic interferon alfa-2 were studied retrospectively. The 
foliow up of 10 months after treatment, the visual acuity had deteriorated compared with the pretreatment value in 21 out of 41 (51%) eyes. Vision improved in some fellow eyes with disciform scars. Side effects were common and often severe. The data suggest that one of the major effects of interferon alfa may be to decrease vascular permeability. While further research may identify a place for interferon alfa in the treatment of choroidal neovascularisation, we were unable to demonstrate that the treatment regimens of systemic interferon alfa we used caused a dramatic benefit to patients with exudative age-related macular degenera- The current treatment of choroidal neovascular membranes, which frequently destroy central vision, is unsatisfactory. Only one quarter of cases in which a choroidal neovascular membrane arises in an eye with age-related macular degeneration can be successfully ablated with a laser,' and at least one half of these eyes suffer recurrences or develop new choroidal neovascular membranes within 5 years.2 The Macular Photocoagulation Study Group found that laser ablation of subfoveal choroidal neovascular membranes (that met the eligibility criteria) resulted in marginally but significantly improved visual acuities and scotomas 2 years after treatment, but this was offset against poorer visual acuity in the treated group compared with the untreated group at 3 months.3 When subfoveal choroidal neovascular membranes were completely ablated except for the foveal component patients had significantly improved vision 1 year after treatment compared with untreated patients, but of those followed for 3 years 92% had lost three or more lines of vision. 4 Remarkable advances over the past decade have identified a number of cytokines that regulate pathological processes such as neoplasia, wound healing, fibrosis, and angiogenesis at the cellular level.5 These raise the possibility ofnovel treatments.
A recent report suggests that systemic interferon alfa-2a treatment may inhibit the growth of choroidal neovascular membranes in eyes with age-related macular degeneration.6 Seven patients with well defined subfoveal membranes were treated with systemic interferon alfa-2a for about 6 weeks. Six patients showed resolution of the membrane on treatment, improved acuity, and smaller scotomas. The diameter of the choroidal neovascular membrane was one disc diameter (1 DD) or less in all six eyes in which the membrane regressed.
Systemic interferon alfa-2 has been used clinically to treat vascular tumours, including pulmonary haemangiomatosis7 and haemangioendotheliomas.8 The antiangiogenic activity of interferon is not entirely understood. Interferon alfa inhibits vascular endothelial cell proliferation in vitro, possibly through the induction of 2',5'-oligoadenylate synthetase which leads to the degradation of viral and cellular RNA. 9 We present herein a retrospective analysis of 48 eyes of 42 patients with age-related macular degeneration who received systemic interferon alfa-2 (either 2a or 2b) treatment for active choroidal neovascular membranes. These patients were treated around the end of 1991 by several groups of Sydney ophthalmologists acting independently and using different protocols. The large number of patients treated no doubt reflects the public awareness of interferon alfa as a treatment for age-related macular degeneration, which was due to a number of reports in the media at that time. The goal of this study was to examine the effects of interferon alfa on the growth and activity of choroidal neovascular membranes in a large group of patients. All groups received interferon alfa-2 subcutaneously for at least 6 weeks, unless side effects forced treatment to be withdrawn. Three different regimens were employed (Table 3) .
INVESTIGATIONS
Fluorescein angiography was performed within 2 weeks before treatment and 5 days after finishing treatment. A full blood examination and liver function tests were performed fortnightly.
Results Table 4 summarises the pathology present, the visual acuity before and after treatment and at the most recent patient visit, and the change in size of the neovascular membrane in each of the 48 eyes of the 42 patients treated. Small foveal neovascular membranes, which were less than 1 DD in size and encroached on the foveal avascular zone, are noted. CF=counting fingers.
HM=hand movements.
NPL=no perception of light.
(17%) (Figs 1, 2) eyes overall, not changed in 16 difference was found between patients receiving (39%), and increased in 18 (44%) (Fig 3) . (Fig 4) . No clear 'treated' eyes, not changed in 27 (66%), and two lines in two (11%), one line in three (16%), and remained stable in 13 (68%). Many patients commented that they seemed to be able to 'see through' the scotoma in the eye with the disciform scar. Less leakage was sometimes noted in these eyes with angiography (Fig 2) but this is difficult to quantify and more attention was paid to the eye with the choroidal neovascular membrane. Our results show that systemic interferon alfa treatment does not cause resolution of a significant number of choroidal neQvascular membranes in the short term. This is at variance with Fung's report6 which found resolution in six out of six patients with small well defined choroidal neovascular membranes encroaching on the foveal avascular zone, although it was not clear whether the patients presented were selected from a large group. Our series included 10 patients who fitted this description, and three of these showed partial resolution, but most either remained the same or deteriorated. Interferon alfa-2a, which was used by Fung, and interferon alfa-2b differ only at the position 23 amino acid, which is arginine or lysine respectively. They are presumed to have equivalent activity although this has not been established. All the patients receiving the higher dose of interferon in our study received it as interferon alfa-2a. The time from the pretreatment angiogram to starting treatment in our series was up to 2 weeks, so rapid deterioration may have occurred in some eyes after angiography.
SIDE EFFECTS
The pretreatment visual acuity was maintained in 51% of eyes at the latest follow up visit with a mean follow up of 10 months. While this result is encouraging, its significance is uncertain. The Macular Photocoagulation Study Group found that 3 months after entry into the study, 52% of patients with untreated subfoveal choroidal neovascular membranes had lost more than two lines of vision.3 In the study of Coscas et al, 20% of untreated eyes had unchanged or improved visual acuity from 1-4 years after treatment. 4 All patients in that study had vision between 20/100 to 20/1000 at entry which suggests they may have had longstanding neovascular membranes. Neovascular membranes of recent onset are more likely to deteriorate subsequently,'0 and the mean duration of symptoms in our patients was only 2-9 months.
The fact that the vision in many eyes deteriorated after treatment suggests that 6 weeks is not long enough. The angiogenic stimulus for choroidal neovascular membranes, which seems to be related to the type and amount of drusen material present," is unlikely to be altered by interferon alfa treatment. Since drusen usually resolve of their own accord, it may be possible to stabilise choroidal neovascular membranes with interferon alfa until the angiogenic stimulus wanes. In this case it may be necessary to treat the patient for many months with smaller doses of interferon alfa. Alternatively, local administration, such as intravitreal or retrobulbar injection, might allow high sustained local concentrations from a lower dose.
Some of the data in this study suggest that interferon alfa treatment may have reduced the leakage of the neovascular membranes. The small improvement of vision in the fellow eye if a disciform scar were present may well have been due to decreasing vision in the 'treated' eye, but it is also consistent with inhibition by interferon alfa of the persistent leakage from a disciform scar, which was frequently found by Teeters and Bird.'2 The fact that acuity deteriorated in the 'treated' eye in fewer patients than did the size of the neovascular membrane may also have been due to decreased leakiness of the membrane, although patients may simply have tried harder to read the chart after going through the arduous treatment programme.
Side effects are a major problem of systemic interferon alfa treatment. Fatigue and a flu-like illness commonly occur, while more serious problems include myelosuppression and cardiac and hepatic toxicity. 3 Some patients in our study developed a life threatening illness during treatment and one died. The severe gastroenterological side effects and mood changes that some of our patients experienced are unusual but can occur with interferon alfa treatment. Previous experience with the drug, which is extensive, has been largely in a younger age group and it should be used in elderly patients with caution. A dose of 21 x 106 IU weekly was intolerable for most ofour patients; even 9x 106 IU weekly was unacceptable in several patients and is unlikely to be tolerated as long term treatment. One of the major challenges in the further evaluation of interferon alfa may be to deliver effective levels of the drug with fewer side effects than we have found.
In this study the patient group was not homogeneous. The absence of a control group precludes any valid statistical analysis. Nevertheless, a number of general conclusions can be drawn on the balance of probabilities from uncontrolled retrospective studies such as this which can be used to direct further research.
The possible benefits of interferon alfa-2 treatment must be balanced against the risks and side effects. Treatment might be more useful if it could be delivered more effectively for an extended period. Although our regimens seemed to stabilise many patients while they were on treatment, side effects were common and often severe, and many patients relapsed after treatment. We were unable to demonstrate that the treatment regimens ofsystemic interferon alfa we used caused any dramatic benefit to patients with exudative age-related macular degeneration, although a significant effect may yet be demonstrated by a controlled clinical trial. 
